Logo image of PRTG

PORTAGE BIOTECH INC (PRTG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRTG - VGG7185A1369 - Common Stock

6.81 USD
-0.15 (-2.16%)
Last: 9/3/2025, 8:00:01 PM
7.4101 USD
+0.6 (+8.81%)
After Hours: 9/3/2025, 8:00:01 PM
Fundamental Rating

1

PRTG gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. PRTG may be in some trouble as it scores bad on both profitability and health. PRTG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRTG had negative earnings in the past year.
In the past year PRTG has reported a negative cash flow from operations.
PRTG had negative earnings in each of the past 5 years.
In the past 5 years PRTG always reported negative operating cash flow.
PRTG Yearly Net Income VS EBIT VS OCF VS FCFPRTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

PRTG has a worse Return On Assets (-304.13%) than 93.54% of its industry peers.
Industry RankSector Rank
ROA -304.13%
ROE N/A
ROIC N/A
ROA(3y)-459.4%
ROA(5y)-279.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRTG Yearly ROA, ROE, ROICPRTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRTG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTG Yearly Profit, Operating, Gross MarginsPRTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, PRTG has more shares outstanding
PRTG has less shares outstanding than it did 5 years ago.
PRTG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRTG Yearly Shares OutstandingPRTG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
PRTG Yearly Total Debt VS Total AssetsPRTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

PRTG has an Altman-Z score of -146.06. This is a bad value and indicates that PRTG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PRTG (-146.06) is worse than 97.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -146.06
ROIC/WACCN/A
WACCN/A
PRTG Yearly LT Debt VS Equity VS FCFPRTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

2.3 Liquidity

PRTG has a Current Ratio of 2.02. This indicates that PRTG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.02, PRTG is doing worse than 74.35% of the companies in the same industry.
PRTG has a Quick Ratio of 2.02. This indicates that PRTG is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.02, PRTG is not doing good in the industry: 73.06% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.02
PRTG Yearly Current Assets VS Current LiabilitesPRTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

PRTG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.66%, which is quite impressive.
EPS 1Y (TTM)92.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PRTG will show a very strong growth in Earnings Per Share. The EPS will grow by 62.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%
EPS Next 5Y62.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRTG Yearly Revenue VS EstimatesPRTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 50M 100M 150M 200M
PRTG Yearly EPS VS EstimatesPRTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRTG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTG Price Earnings VS Forward Price EarningsPRTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTG Per share dataPRTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

PRTG's earnings are expected to decrease with -27.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%

More info and screens

0

5. Dividend

5.1 Amount

PRTG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PORTAGE BIOTECH INC

NASDAQ:PRTG (9/3/2025, 8:00:01 PM)

After market: 7.4101 +0.6 (+8.81%)

6.81

-0.15 (-2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-25 2025-08-25
Earnings (Next)11-24 2025-11-24
Inst Owners2.21%
Inst Owner Change0%
Ins Owners35.54%
Ins Owner ChangeN/A
Market Cap15.53M
Revenue(TTM)N/A
Net Income(TTM)-6.77M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -304.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-459.4%
ROA(5y)-279.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 2.02
Altman-Z -146.06
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.91%
EPS Next Y0%
EPS Next 2Y-68.71%
EPS Next 3Y-27.59%
EPS Next 5Y62.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.8%
OCF growth 3YN/A
OCF growth 5YN/A

PORTAGE BIOTECH INC / PRTG FAQ

Can you provide the ChartMill fundamental rating for PORTAGE BIOTECH INC?

ChartMill assigns a fundamental rating of 1 / 10 to PRTG.


Can you provide the valuation status for PORTAGE BIOTECH INC?

ChartMill assigns a valuation rating of 0 / 10 to PORTAGE BIOTECH INC (PRTG). This can be considered as Overvalued.


How profitable is PORTAGE BIOTECH INC (PRTG) stock?

PORTAGE BIOTECH INC (PRTG) has a profitability rating of 0 / 10.


What is the earnings growth outlook for PORTAGE BIOTECH INC?

The Earnings per Share (EPS) of PORTAGE BIOTECH INC (PRTG) is expected to decline by 0% in the next year.